ARCA biopharma Announces First Quarter 2024 Financial Result

ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee o

Related Keywords

Colorado , United States , Delaware , Jeff Dekker , Christopherd Ozeroff , Thomasa Keuer , Michael Bristow , Continuous Service , University Of Colorado , Atlas Merger Sub , Nasdaq , Atlas Merger Sub Corp , Exchange Commission , Oruka Therapeutics Inc , Company On Linkedin , Oruka Therapeutics , Thomas Keuer , Special Committee , Merger Agreement , First Merger , Merger Sub , Internal Revenue Code , Current Report , Chief Executive Officer , Separation Agreement , Consulting Agreement , Incentive Plan , Chief Operating Officer , Senior Vice President , General Counsel , Private Securities Litigation Reform Act , Proposed Transactions , Securities Act , Additional Information About , Proposed Transactions Will , Annual Report , Media Contact ,